Literature DB >> 35062076

Essentiality, relevance, and efficacy of adjuvant/combinational therapy in the management of thyroid dysfunctions.

Diptimayee Das1, Antara Banerjee2, Atala Bihari Jena3, Asim K Duttaroy4, Surajit Pathak5.   

Abstract

Thyroid dysfunction is the most prevalent endocrine disorder worldwide having an epidemiology of 11% in Indians, 4.6% in the United Kingdom, and 2% in the United States of America among the overall population. The common thyroid disorders include hypothyroidism, hyperthyroidism, Hashimoto's thyroiditis, and thyroid cancer. This review briefly elaborates the molecular regulation and mechanism of thyroid hormone, and its associated thyroid disorders. The thyroid hormones regulate critical biochemical functions in brain development and function. Hypothyroidism is mainly associated with dysregulation of cytokines, increased ROS production, and altered signal transduction in major regions of the brain. In addition, it is associated with reduced antioxidant capacity and increased oxidative stress in humans. Though 70% of thyroid disorders are caused by heredity, environmental factors have a significant influence in developing autoimmune thyroid disorders in people who are predisposed to them. This drives us to understand the relationship between environmental factors and thyroid dysregulated disorders. The treatment option for the thyroid disorder includes antithyroid medications, receiving radioactive iodine therapy, or surgery at a critical stage. However, antithyroid drugs are not typically used long-term in thyroid disease due to the high recurrence rate. Adjuvant treatment of antioxidants can produce better outcomes with anti-thyroid drug treatment. Thus, Adjuvant therapy has been proven as an effective strategy for managing thyroid dysfunction, herbal remedies can be used to treat thyroid dysfunction in the future, which in turn can reduce the prevalence of thyroid disorders.
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Adjuvant therapy; Hyperthyroidism; Hypothyroidism; Radioiodine therapy; Thyroid dysfunction

Mesh:

Substances:

Year:  2022        PMID: 35062076     DOI: 10.1016/j.biopha.2022.112613

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

1.  The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules.

Authors:  Christian Happel; Wolfgang Tilman Kranert; Benjamin Bockisch; Amir Sabet; Frank Grünwald; Daniel Groener
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.